GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » FCF Margin %

Oruka Therapeutics (FRA:HQ1) FCF Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oruka Therapeutics's Free Cash Flow for the six months ended in Dec. 2024 was €0.00 Mil. Oruka Therapeutics's Revenue for the six months ended in Dec. 2024 was €0.00 Mil. Therefore, Oruka Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Oruka Therapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Oruka Therapeutics's FCF Margin % or its related term are showing as below:


FRA:HQ1's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.22
* Ranked among companies with meaningful FCF Margin % only.

Oruka Therapeutics FCF Margin % Historical Data

The historical data trend for Oruka Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics FCF Margin % Chart

Oruka Therapeutics Annual Data
Trend Dec24
FCF Margin %
-

Oruka Therapeutics Semi-Annual Data
Dec24
FCF Margin % -

Competitive Comparison of Oruka Therapeutics's FCF Margin %

For the Biotechnology subindustry, Oruka Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's FCF Margin % falls into.


;
;

Oruka Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oruka Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=0/0
= %

Oruka Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » FCF Margin %
Comparable Companies
PGEN CGEM MNMD VERV RLAY PHAT TBPH OMER AUTL CRMD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ORKA:USA HQ1:Germany
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines